There are definitely things to like about United Therapeutics. With the recent decline, the stock trades at 10.2× forward price-to-earnings (or $308.27 per share). Is now the right time to buy?

United Therapeutics has high revenue growth and low debt. Read why UTHR stock is undervalued with solid financial metrics and ...

A month has gone by since the last earnings report for United Therapeutics (UTHR). Shares have lost about 4.8% in that time frame, underperforming the S&P 500. Will the recent negative trend ...

3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever United Therapeutics (NASDAQ:UTHR – Get Free Report) last released its quarterly earnings results ...

The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% ...

It is also one of the 10 best healthcare stocks for long-term investment. For the full year of 2024, United Therapeutics (NASDAQ:UTHR) reported record revenues of $2.88 billion, reflecting 24% ...

In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ ... It is also one of the 10 best healthcare stocks for long-term investment.